Medicare Enrolled
Dr. Antoinette Matthews, M.D.
Internal Medicine · Dallas, TX
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Matthews from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Matthews?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Matthews
Dr. Antoinette Matthews is an internal medicine specialist in Dallas, TX, with 11 years of NPI registration. Based on federal Medicare data, Dr. Matthews performed 28,805 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Dr. Matthews received a total of $7,234 from 33 pharmaceutical and/or device companies across 234 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Matthews is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 11 years of NPI registration
▲ Top 2% volume in TX
$7,234 industry payments
Medicare Practice Summary — 2023
Medicare Utilization ↗28,805
Medicare services
Top 2% in TX for internal medicine
Not available
Unique patients (not deduplicated)
$17
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Pembrolizumab injection (Keytruda) | 8,400 | $43 | $136 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
6,750 | $0 | $5 |
| Paclitaxel chemotherapy injection | 4,914 | $0 | $8 |
| Contrast dye for imaging (iodine-based) A contrast agent containing 300-399 mg/ml of iodine used to enhance imaging studies. It is administered per milliliter to improve the visibility of internal structures. |
3,588 | $0 | $3 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,095 | $0 | $1 |
| Anti-nausea injection (Aloxi/palonosetron) | 660 | $1 | $114 |
| Injection, granisetron hydrochloride, 100 mcg | 510 | $0 | $24 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
287 | $91 | $368 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 250 | $3 | $373 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
219 | $8 | $20 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
216 | $23 | $157 |
| Comprehensive metabolic blood panel A blood test that measures a group of chemicals, including glucose, electrolytes, and kidney and liver function markers. |
214 | $10 | $64 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
200 | $8 | $36 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
195 | $102 | $707 |
| Carboplatin chemotherapy injection, 50 mg Administration of a 50 mg dose of carboplatin, a chemotherapy medication, via injection. |
164 | $2 | $300 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
156 | $12 | $108 |
| Fluorouracil injection, 500 mg Administration of a 500 mg dose of fluorouracil medication via injection. |
134 | $2 | $13 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 95 | $20 | $128 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
78 | $132 | $496 |
| Carcinoembryonic antigen (CEA) level test A blood test that measures the level of carcinoembryonic antigen (CEA) protein. This test is used to monitor certain types of cancer. |
72 | $19 | $99 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
61 | $50 | $344 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
56 | $1 | $7 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
48 | $6 | $431 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
45 | $22 | $161 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
43 | $11 | $96 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
41 | $1 | $8 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
38 | $46 | $313 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
38 | $2 | $19 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
35 | $55 | $211 |
| CT scan of chest with contrast A computed tomography scan of the chest using a contrast dye to enhance the visibility of internal structures. |
33 | $54 | $821 |
| CT scan of abdomen and pelvis with contrast A CT scan that uses dye to create detailed images of the abdomen and pelvis. This imaging test helps doctors examine internal organs and structures in these areas. |
29 | $170 | $1,067 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
29 | $62 | $247 |
| New patient office visit, complex (60-74 min) | 19 | $158 | $709 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
17 | $10 | $75 |
| Concurrent intravenous infusion Administration of medication or fluid into a vein for therapy, prevention, or diagnosis while another infusion is being given. |
17 | $16 | $94 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
17 | $65 | $250 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 15 | $91 | $657 |
| IV chemotherapy initiation with community continuation Initiation of an intravenous chemotherapy infusion in a clinic using clinic supplies, with continuation of the infusion in a community setting such as home or assisted living. |
14 | $132 | $500 |
| Nuclear medicine scan from skull base to mid-thigh with CT A nuclear medicine imaging study covering the area from the base of the skull to the middle of the thighs, performed alongside a CT scan. |
13 | $1,191 | $4,802 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
2.0% high complexity
93.5% medium
4.5% routine
Industry Payment Transparency
Open Payments through 2024 ↗$7,234
Total received (2018-2024)
Avg $1,033/year across 7 years
Top 12% in TX for internal medicine
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
33
Companies
234
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$2,328
2023
$1,403
2022
$768
2021
$329
2020
$384
2019
$1,690
2018
$332
Payments by company (2024)
Novartis Pharmaceuticals Corporation
$1,024
AstraZeneca Pharmaceuticals LP
$441
Daiichi Sankyo Inc.
$420
Stemline Therapeutics Inc.
$181
Merck Sharp & Dohme LLC
$97
Genentech USA, Inc.
$45
Gilead Sciences, Inc.
$40
Tempus AI, Inc
$38
Regeneron Healthcare Solutions, Inc.
$22
SOBI, INC
$20
Top 3 companies account for 80.9% of 2024 payments
All-time payments by company (2018-2024) ›
Novartis Pharmaceuticals Corporation
$1,455
Daiichi Sankyo Inc.
$1,281
AstraZeneca Pharmaceuticals LP
$800
Amgen Inc.
$474
NOVARTIS PHARMACEUTICALS CORPORATION
$283
Stemline Therapeutics Inc.
$276
Celgene Corporation
$256
Merck Sharp & Dohme Corporation
$239
Incyte Corporation
$206
Takeda Pharmaceuticals U.S.A., Inc.
$189
Tactile Systems Technology Inc
$187
Astellas Pharma US Inc
$185
Genentech USA, Inc.
$178
Novocure Inc.
$159
Merck Sharp & Dohme LLC
$141
GENZYME CORPORATION
$125
Seattle Genetics, Inc.
$107
Gilead Sciences, Inc.
$96
Janssen Biotech, Inc.
$95
Clovis Oncology, Inc.
$75
PFIZER INC.
$55
Adaptive Biotechnologies Corporation
$52
Acrotech Biopharma LLC
$45
Epizyme, Inc.,
$43
Regeneron Healthcare Solutions, Inc.
$42
Tempus AI, Inc
$38
Pharmacyclics LLC, an AbbVie Company
$29
Seagen Inc.
$23
Boston Scientific Corporation
$21
Pharmacyclics LLC, An AbbVie Company
$21
Sobi, Inc
$21
SOBI, INC
$20
Lilly USA, LLC
$17
Top 3 companies account for 48.9% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · Alecensa · BELEODAQ · Blincyto · CALQUENCE · DOPTELET · ELITEK · ENHERTU · EPKINLY · Enhertu · Flexitouch Plus · GAMIFANT · Herceptin · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · Itovebi · JAKAFI · KEYTRUDA · KISQALI · Kyprolis · LIBTAYO · LYNPARZA · MONJUVI · MVASI · NINLARO · Neulasta · Oncology · Orserdu · PIQRAY · Revlimid · Rubraca · SPYGLASS · TABRECTA · TAGRISSO · TAZVERIK · TECENTRIQ · TUKYSA · Trodelvy · VELCADE · VERZENIO · clonoSEQ
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Internal medicine physicians in nearby ZIP areas
2,123
County median income
$74,149
Nearest hospital to ZIP centroid (approximate)
BAYLOR UNIVERSITY MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Matthews is a mixed practice specialist, with above-average Medicare volume (top 2% in TX).
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Matthews experienced with pembrolizumab injection (keytruda)?
Based on Medicare claims data, Dr. Matthews performed 8,400 pembrolizumab injection (keytruda) services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Matthews receive payments from pharmaceutical companies?
Yes. Dr. Matthews received a total of $7,234 from 33 companies across 234 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Matthews's costs compare to other internal medicine physicians in Dallas?
Dr. Matthews's average Medicare payment per service is $17. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Matthews) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Same specialty & city
Internal Medicine Physicians in Dallas
Browse internal medicine physicians in Dallas ranked by procedure volume and transparency data.
Highest volume
Top Internal Medicine Physicians in TX
Internal medicine physicians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Internal Medicine Physicians in TX
Which TX internal medicine physicians receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
Daiichi Sankyo Inc. Payments to Doctors
See all physicians who received payments from Daiichi Sankyo Inc.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology